Association between treatment failure and hospitalization after receipt of neutralizing monoclonal antibody treatment for COVID-19 outpatients

BACKGROUND: Neutralizing monoclonal antibodies (mAbs) are highly effective in reducing hospitalization and mortality among early symptomatic COVID-19 patients in clinical trials and real-world data. While resistance to some mAbs has since emerged among new variants, characteristics associated with t...

Descripción completa

Detalles Bibliográficos
Autores principales: Douin, David J., Wogu, Adane F., Beaty, Laurel E., Carlson, Nichole E., Bennett, Tellen D., Aggarwal, Neil R., Mayer, David A., Ong, Toan C., Russell, Seth, Steele, Jeffrey, Peers, Jennifer L., Molina, Kyle C., Wynia, Matthew K., Ginde, Adit A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639288/
https://www.ncbi.nlm.nih.gov/pubmed/36344927
http://dx.doi.org/10.1186/s12879-022-07819-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639288/
https://www.ncbi.nlm.nih.gov/pubmed/36344927
http://dx.doi.org/10.1186/s12879-022-07819-z

Ejemplares similares